Core Insights - Plus Therapeutics, Inc. has appointed Kyle Guse, J.D., M.B.A. to its Board of Directors, where he will chair the Audit Committee and serve on the Compensation Committee [1][2] - Guse brings over 30 years of experience in financial, transactional, and operational roles, including significant positions at Atossa Therapeutics, Inc. and DDC Enterprise Ltd. [2][3] - The company is focused on developing targeted radiotherapeutics for central nervous system cancers, with products like REYOBIQ™ and CNSide, aiming to enhance clinical outcomes [4] Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company headquartered in Houston, Texas, specializing in targeted radiotherapeutics for challenging CNS cancers [4] - The company combines image-guided local beta radiation with targeted drug delivery approaches, advancing a pipeline that includes programs for leptomeningeal metastases and recurrent glioblastoma [4] - Plus Therapeutics has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [4]
Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors